Bladder Cancer

Latest News

FDA logo
FDA grants priority review to durvalumab for muscle-invasive bladder cancer

December 6th 2024

The priority review decision is based on results of the phase 3 NIAGARA study (NCT03732677).

Trials launch of nadofaragene firadenovec in bladder cancer
Trials launch of nadofaragene firadenovec in bladder cancer

December 3rd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer
Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

December 2nd 2024

UGN-101 demonstrates long-term durability in low-grade UTUC
UGN-101 demonstrates long-term durability in low-grade UTUC

November 26th 2024

QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC
QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC

November 19th 2024

© 2024 MJH Life Sciences

All rights reserved.